[{"orgOrder":0,"company":"Conduit Pharma","sponsor":"Charles River Laboratories, Inc","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"AZD1656","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Conduit Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Conduit Pharma \/ Charles River Laboratories, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Conduit Pharma \/ Charles River Laboratories, Inc"},{"orgOrder":0,"company":"Conduit Pharma","sponsor":"Murphy Canyon Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"AZD5904","moa":"MPO","graph1":"Endocrinology","graph2":"Phase II","graph3":"Conduit Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Conduit Pharma \/ Murphy Canyon Acquisition Corp.","highestDevelopmentStatusID":"8","companyTruncated":"Conduit Pharma \/ Murphy Canyon Acquisition Corp."},{"orgOrder":0,"company":"Conduit Pharma","sponsor":"Murphy Canyon Acquisition","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Merger","leadProduct":"AZD5904","moa":"MPO","graph1":"Endocrinology","graph2":"Phase II","graph3":"Conduit Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Conduit Pharma \/ Murphy Canyon Acquisition","highestDevelopmentStatusID":"8","companyTruncated":"Conduit Pharma \/ Murphy Canyon Acquisition"},{"orgOrder":0,"company":"Conduit Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AZD1656","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Conduit Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Conduit Pharma \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"Conduit Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"Conduit Pharma","sponsor":"Sarborg Limited","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"AZD1656","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Conduit Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Conduit Pharma \/ Sarborg Limited","highestDevelopmentStatusID":"8","companyTruncated":"Conduit Pharma \/ Sarborg Limited"}]

Find Clinical Drug Pipeline Developments & Deals by Conduit Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BioTrinity 2025
                          Not Confirmed
                          BioTrinity 2025
                          Not Confirmed

                          Details : AZD1656 is a glucokinase activator small molecule drug candidate, which is currently being evaluated for the treatment of patients with lupus nephritis.

                          Product Name : AZD1656

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 20, 2025

                          Lead Product(s) : AZD1656

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase II

                          Sponsor : Sarborg Limited

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          BioTrinity 2025
                          Not Confirmed
                          BioTrinity 2025
                          Not Confirmed

                          Details : Conduit will leverage Charles River’s expertise in immunology and preclinical research to help in development of AZD1656 for Lupus Nephritis.

                          Product Name : AZD1656

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          February 13, 2025

                          Lead Product(s) : AZD1656

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase II

                          Sponsor : Charles River Laboratories, Inc

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          BioTrinity 2025
                          Not Confirmed
                          BioTrinity 2025
                          Not Confirmed

                          Details : AZD1656, a HK-4 glucokinase activator, is now being repurposed by Conduit for for the treatment of systemic lupus erythematosus (including lupus nephritis) and ANCA-associated vasculitis.

                          Product Name : AZD1656

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 08, 2024

                          Lead Product(s) : AZD1656

                          Therapeutic Area : Immunology

                          Highest Development Status : Preclinical

                          Sponsor : AstraZeneca

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          BioTrinity 2025
                          Not Confirmed
                          BioTrinity 2025
                          Not Confirmed

                          Details : The combined company will accelerate development of Conduit’s autoimmune disease and idiopathic male infertility pipeline, including AZD5904, a potent orally bioavailable MPO inhibitor.

                          Product Name : AZD5904

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          September 22, 2023

                          Lead Product(s) : AZD5904

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase II

                          Sponsor : Murphy Canyon Acquisition

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank

                          05

                          BioTrinity 2025
                          Not Confirmed
                          BioTrinity 2025
                          Not Confirmed

                          Details : AZD5904 is a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

                          Product Name : AZD5904

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          September 11, 2022

                          Lead Product(s) : AZD5904

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Sponsor : Murphy Canyon Acquisition Corp.

                          Deal Size : $27.0 million

                          Deal Type : Private Placement

                          blank